<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hyaluronidase: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hyaluronidase: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Hyaluronidase: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8657" href="/d/html/8657.html" rel="external">see "Hyaluronidase: Drug information"</a> and <a class="drug drug_patient" data-topicid="11538" href="/d/html/11538.html" rel="external">see "Hyaluronidase: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F179308"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Amphadase;</li>
<li>Hylenex;</li>
<li>Vitrase [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1047693"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote, Extravasation</span></li></ul></div>
<div class="block don drugH1Div" id="F53462468"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="31c8f817-d2c5-460f-b222-73f4eb9ef788">Skin test</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin test:</b> Intradermal: 0.02 mL (Amphadase 3 units, Hylenex 3 units, or Vitrase 4 units) of a 150 units/mL (Amphadase, Hylenex) or 200 units/mL (Vitrase) solution. Positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20 to 30 minutes with localized itching (transient erythema is not considered a positive reaction). Skin testing is not necessary prior to use for extravasation management.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d40bc1b-76c8-4ad8-9515-fbb6dd3439ea">Dehydration, treatment to facilitate subcutaneous fluid replacement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dehydration, treatment to facilitate subcutaneous fluid replacement:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Added to replacement SubQ solution:</i> SubQ: Dose dependent on volume to be infused; maximum daily volume of subcutaneous fluid administration is 25 mL/kg/<b>day</b> and the rate of administration should not exceed 2 mL/minute.</p>
<p style="text-indent:-2em;margin-left:6em;">Amphadase, Hylenex: 150 units facilitates absorption of ≥1,000 mL of solution.</p>
<p style="text-indent:-2em;margin-left:6em;">Vitrase: 200 units facilitates absorption of ≥1,000 mL of solution.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8d06caa2-49e0-4a6c-a902-bfad71a7ee44">Extravasation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation:</b> Limited data available: SubQ, intradermal: Use 5 separate 0.2 mL injections of a 15 or 150 units/mL solution into the extravasation site at the leading edge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-20417890','lexi-content-ref-24714850','lexi-content-ref-6628223','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-20417890','lexi-content-ref-24714850','lexi-content-ref-6628223','lexi-content-ref-24420913'])">Ref</a></span>). <b>Note:</b> Some centers determine the concentration of hyaluronidase based upon the volume of extravasation, so for smaller extravasation volumes (&lt;100 mL), a less concentrated solution (15 units/mL) has been used or by the medication risk of tissue toxicity (based on pH, osmolarity, known tissue toxicity) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6628223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6628223'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F179326"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="31c8f817-d2c5-460f-b222-73f4eb9ef788">Skin test</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin test:</b> Infants, Children, and Adolescents: Intradermal: 0.02 mL (Amphadase 3 units, Hylenex 3 units, or Vitrase 4 units) of a 150 units/mL (Amphadase, Hylenex) or 200 units/mL (Vitrase) solution. Positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20 to 30 minutes with localized itching (transient erythema is not considered a positive reaction). Skin testing is not necessary prior to use for extravasation management.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d40bc1b-76c8-4ad8-9515-fbb6dd3439ea">Dehydration, treatment to facilitate subcutaneous fluid replacement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dehydration, treatment to facilitate subcutaneous fluid replacement:</b> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>SubQ following SubQ infusion</i>: SubQ: Dose dependent on volume to be infused; administer into rubber tubing close to needle after initiation of subcutaneous isotonic fluid; fluid administration rate is dependent upon age, weight, and clinical condition of the patient, as well as laboratory determinations.</p>
<p style="text-indent:-2em;margin-left:6em;">Amphadase: 150 units facilitates absorption of ≥1,000 mL of solution.</p>
<p style="text-indent:-2em;margin-left:6em;">Vitrase: 200 units facilitates absorption of ≥1,000 mL of solution.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>SubQ prior to SubQ infusion:</i> SubQ: Dose dependent on volume to be infused; administer into rubber tubing close to needle prior to initiation of subcutaneous isotonic fluid; fluid administration rate is dependent upon age, weight, and clinical condition of the patient, as well as laboratory determinations.</p>
<p style="text-indent:-2em;margin-left:6em;">Amphadase, Hylenex: 150 units facilitates absorption of ≥1,000 mL of solution.</p>
<p style="text-indent:-2em;margin-left:6em;">Vitrase: 200 units facilitates absorption of ≥1,000 mL of solution.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Added to SubQ replacement solution:</i> SubQ: Dose dependent on volume to be infused, generally recommended for smaller volumes (eg, 200 mL); rate and volume of a single clysis should not exceed those used for infusion of IV fluids.</p>
<p style="text-indent:-2em;margin-left:6em;">Amphadase, Hylenex: 150 units facilitates absorption of ≥1,000 mL of solution.</p>
<p style="text-indent:-2em;margin-left:6em;">Vitrase: 200 units facilitates absorption of ≥1,000 mL of solution.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d9c2cee-7ac6-4cc3-80c6-d2c85f38002e">Dispersion/absorption enhancement of injected drugs</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dispersion/absorption enhancement of injected drugs:</b> Children and Adolescents: Amphadase, Hylenex, Vitrase: 50 to 300 units added to injection solution (consult compatibility reference prior to mixing); some preparations (Hylenex) may be administered SubQ prior to drug needing dispersed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dispersion of subcutaneous immunoglobulin: </i>Limited data available: Hylenex: Children ≥2 years and Adolescents: 75 units of hyaluronidase per gram of immunoglobulin; hyaluronidase added to dose of subcutaneous immunoglobulin. Dosing based on open-label prospective studies in patients with primary immunodeficiencies requiring immunoglobulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22846381','lexi-content-ref-27468136','lexi-content-ref-27220317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22846381','lexi-content-ref-27468136','lexi-content-ref-27220317'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8d06caa2-49e0-4a6c-a902-bfad71a7ee44">Extravasation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation:</b> Limited data available: Infants, Children, and Adolescents: SubQ, intradermal: Use 4 to 5 separate 0.2 mL injections of a 15 or 150 units/mL solution into the extravasation site at the leading edge as soon as possible (preferably within 1 hour) after extravasation is recognized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-24714850','lexi-content-ref-24420913','lexi-content-ref-Sokol.1','lexi-content-ref-20159411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-24714850','lexi-content-ref-24420913','lexi-content-ref-Sokol.1','lexi-content-ref-20159411'])">Ref</a></span>). <b>Note:</b> Some centers may determine concentration of hyaluronidase based upon the medication risk of tissue toxicity (risk determined by pH, osmolarity, known tissue toxicity) or by volume of extravasation, so for smaller volumes (&lt;100 mL), a less concentrated solution (15 units/mL) has been used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-6628223','lexi-content-ref-Sokol.1','lexi-content-ref-20159411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-6628223','lexi-content-ref-Sokol.1','lexi-content-ref-20159411'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ec6e0b12-d06a-4fa8-8fa9-48d591b7e2da">Urography, subcutaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urography, subcutaneous:</b> Infants, Children, and Adolescents: SubQ: 75 units over each scapula followed by injection of contrast medium at the same site; patient should be in the prone position during drug administration.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51113037"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; hyaluronidase exerts its effects locally and is rapidly inactivated in the blood; adverse effects would not be expected.</p></div>
<div class="block dohp drugH1Div" id="F51113038"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; hyaluronidase exerts its effects locally and is rapidly inactivated in the blood; adverse effects would not be expected.</p></div>
<div class="block doa drugH1Div" id="F179310"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8657" href="/d/html/8657.html" rel="external">see "Hyaluronidase: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="731f06f8-183f-4ea3-97da-da5c22293d71">Dispersion and absorption of injected drugs</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dispersion and absorption of injected drugs (adjunctive agent):</b>
<b>SUBQ:</b> 50 to 300 units (usual dose: 150 units) either injected prior to drug administration or added to injection solution (consult compatibility reference prior to mixing).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d1436790-f5af-43d5-8b15-c07cd41c0a01">Extravasation management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation management (off-label use):</b>
<b>Note:</b> Administer as soon as extravasation is recognized. Do not use for extravasation of vasoconstrictors (eg, dopamine, norepinephrine [manage with phentolamine]). For extravasation management, skin testing is not necessary prior to use. The concentration of doses used to manage extravasation ranges from <b>15 units/mL to 150 units/mL</b>; refer to specific vesicant (below) for a description of doses/concentrations used in published case reports and/or reviews:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Aminophylline, amiodarone, calcium solutions<i>, nafcillin, </i> parenteral nutrition/amino acid (4.25%), potassium solutions, and sodium chloride (&gt;1%) extravasation:</i>
<b>Intradermal or SUBQ:</b> Inject a total of 1 mL (15 units/mL) as 5 separate 0.2 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer IV through the infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28947526','lexi-content-ref-6628223','lexi-content-ref-36938775','lexi-content-ref-Zenk.1981.b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28947526','lexi-content-ref-6628223','lexi-content-ref-36938775','lexi-content-ref-Zenk.1981.b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Contrast media extravasation:</i>
<b>Note: </b>Information conflicts regarding hyaluronidase in contrast media extravasation management; the American College of Radiology (ACR) Manual on Contrast Media does not recommend hyaluronidase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACT.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACT.1'])">Ref</a></span>), while other sources suggest its utility for inoperable cases with compartment syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">If using hyaluronidase: <b>Intradermal or SUBQ:</b> Dose varies based on the size of infiltration; inject a total of 5 to 250 units (~100 mL contrast reabsorbed per 15 units of hyaluronidase) around the site of extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dextrose 10% to &lt;50% extravasation:</i>
<b>Intradermal or SUBQ:</b> Inject a total of 1 mL (15 units/mL) as 5 separate 0.2 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer IV through infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6628223','lexi-content-ref-36938775','lexi-content-ref-Zenk.1981.b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6628223','lexi-content-ref-36938775','lexi-content-ref-Zenk.1981.b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dextrose 50% extravasation:</i>
<b>Intradermal or SUBQ:</b> Inject a total of 1 mL (150 units/mL) as 5 separate 0.2 mL injections administered along the leading edge of erythema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20159411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20159411'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mannitol extravasation:</i>
<b> Intradermal or SUBQ:</b> Inject a total of 1 mL (15 units/mL) as 5 separate 0.2 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer IV through the infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Paclitaxel extravasation:</i>
<b>IV:</b> Clinical experience suggests hyaluronidase may be used in the management of paclitaxel extravasations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449','lexi-content-ref-12690542']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449','lexi-content-ref-12690542'])">Ref</a></span>); data is limited. If using hyaluronidase, administer 1 to 6 mL (150 units/mL) into existing IV line, and/or, if needle/cannula has been removed, inject SUBQ in a clockwise manner around area of extravasation. Usual dose is 1 mL hyaluronidase for each 1 mL of extravasated drug; may repeat several times over the next 3 to 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15151940','lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15151940','lexi-content-ref-22997449'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Sodium bicarbonate extravasation: </i>
<b>Intradermal or </b>
<b>SUBQ:</b> Inject a total of 1 mL (15 units/mL) as 5 separate 0.2 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer IV through the infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Vinca alkaloid (vinblastine, vincristine, vindesine, vinorelbine) extravasation:</i></p>
<p style="text-indent:-2em;margin-left:6em;">If needle/cannula still in place:<b> IV:</b> After gently aspirating to remove extravasated vesicant, administer 1 to 6 mL hyaluronidase (150 units/mL) into existing IV line; the usual dose is 1 mL hyaluronidase for each 1 mL of extravasated drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449','lexi-content-ref-21255716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449','lexi-content-ref-21255716'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">If needle/cannula has been removed:<b> SUBQ:</b> Inject 1 to 6 mL (150 units/mL) in a clock wise manner using 1 mL for every 1 mL of drug extravasated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21255716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21255716'])">Ref</a></span>) <b>or</b> administer 1 mL (150 units/mL) as 5 separate 0.2 mL injections (using a 25-gauge needle) into the extravasation site (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Polovich.2009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Polovich.2009'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6e3602aa-06cd-4284-b1ab-393f70e98305">Subcutaneous fluid administration</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Subcutaneous fluid administration (hypodermoclysis adjunctive agent):</b>
<b>SUBQ:</b> 150 units (Amphadase and Hylenex) or 200 units (Vitrase) followed by SUBQ isotonic fluid administration ≥1,000 mL <b>or</b> may be added to small volumes (≤200 mL) of SUBQ replacement fluid. Rate and volume of a single hypodermoclysis should not exceed those used for infusion of IV fluids.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990114"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50987408"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F179284"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Edema</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Injection site reaction</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylactic-like reactions (retrobulbar block or IV injections), anaphylaxis, angioedema, hypersensitivity reaction, urticaria</p></div>
<div class="block coi drugH1Div" id="F179297"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to hyaluronidase or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F179281"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Use with caution in patients with reported history of bee sting allergy; hyaluronidase is an active component in bee venom (Lee 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Albumin: Some products may contain albumin; products containing human albumin may carry a remote risk of viral transmission, including a theoretical risk of Creutzfeldt-Jakob disease transmission.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: For labeled indications, do not administer intravenously (enzyme is rapidly inactivated and desired effects will not be produced); do not inject in or around infected or inflamed areas; may spread localized infection. Do not apply directly to the cornea; not for topical use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Hyaluronidase is ineffective for extravasation management of vasoconstrictors (eg, dopamine, epinephrine, norepinephrine, phenylephrine, vasopressin) or to reduce swelling of bites or stings; do not use in these settings.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sensitization to hyaluronidase may occur; a skin test may be performed to determine hypersensitivity by administering 0.02 mL of hyaluronidase intradermally. A positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20 to 30 minutes with localized itching (transient erythema is not considered a positive reaction). Discontinue hyaluronidase if sensitization occurs. Skin testing is not necessary prior to use for extravasation management.</p></div>
<div class="block foc drugH1Div" id="F179291"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amphadase: 150 units/mL (1 mL) [contains edetate (edta) disodium, thimerosal (thiomersal)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hylenex: 150 units/mL (1 mL) [contains albumin human, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vitrase: 200 units/mL (1.2 mL [DSC]) [contains lactose]</p></div>
<div class="block geq drugH1Div" id="F179278"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F5164759"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Amphadase Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 units/mL (per mL): $66.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Hylenex Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 units/mL (per mL): $66.96</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52612984"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Do not administer IV (enzyme is rapidly inactivated and desired effects will not be produced)</p>
<p style="text-indent:-2em;margin-left:2em;">Extravasation management: May administer undiluted (150 units/mL) or dilutions may be used. Infiltrate area of extravasation with 4 to 5 small injections at the leading edge; use 25-, 27-, or 30-gauge needles and change needle between each skin entry to prevent bacterial contamination and minimize pain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20417890','lexi-content-ref-Sokol.1','lexi-content-ref-Zenk.1981.b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20417890','lexi-content-ref-Sokol.1','lexi-content-ref-Zenk.1981.b'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F179294"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For SUBQ administration, lightly pinch skin up and insert needle/catheter. Do <b>not</b> administer IV for labeled uses (enzyme is rapidly inactivated and desired effects will not be produced).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Extravasation management (off-label use):</b> Stop vesicant infusion immediately; leave needle/cannula in place temporarily but do <b>NOT</b> flush the line; if appropriate, gently aspirate extravasated solution from the IV line, then remove needle/cannula. Keep needle/cannula in place for vinca alkaloid extravasation. Elevate extremity and apply dry, warm compresses or dry, cold compresses as appropriate.</p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase administration:</p>
<p style="text-indent:-2em;margin-left:4em;">Local administration: <b>Intradermal or SUBQ:</b> Inject around the site of extravasation; if IV catheter remains in place, administer IV through the infiltrated catheter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Vinca alkaloids: If needle/cannula still in place, administer 1 to 6 mL hyaluronidase (150 units/mL) into the existing IV line; the usual dose is 1 mL hyaluronidase for each 1 mL of extravasated drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449','lexi-content-ref-21255716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449','lexi-content-ref-21255716'])">Ref</a></span>). If needle/cannula has been removed, inject 1 to 6 mL (150 units/mL) SUBQ in a clockwise manner using 1 mL for 1 mL of drug extravasated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21255716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21255716'])">Ref</a></span>) <b>or</b> administer 1 mL (150 units/mL) as 5 separate 0.2 mL injections (25-gauge needle) SUBQ into the extravasation site (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Polovich.2009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Polovich.2009'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F179304"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Amphadase, Hylenex: Store intact vials in refrigerator at 2°C to 8°C (36°F to 46°F); do not freeze.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Vitrase: Store intact vials in refrigerator at 2°C to 8°C (36°F to 46°F); do not freeze. Protect from light. If adding to other injectable solutions, store admixture at 15°C to 25°C (59°F to 77°F) and use within 6 hours.</p></div>
<div class="block usep drugH1Div" id="F53567194"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Adjunct therapy to increase rate of absorption of parenteral fluids given by hypodermoclysis for hydration (FDA approved in all ages); adjunct therapy to increase the dispersion and absorption of other drugs (FDA approved in pediatric patients [age not specified] and adults); adjunct therapy in subcutaneous urography for improving resorption of radiopaque agents (FDA approved in pediatric patients [age not specified] and adults); has also been used in the management of IV extravasations.</p></div>
<div class="block cyt drugH1Div" id="F13299453"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F179286"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: Hyaluronidase may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.  Management: Do not use hyaluronidase to enhance the dispersion or absorption of alpha-/beta-agonists. Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihistamines: May diminish the therapeutic effect of Hyaluronidase.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May diminish the therapeutic effect of Hyaluronidase.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Hyaluronidase may enhance the adverse/toxic effect of Local Anesthetics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenylephrine (Systemic): Hyaluronidase may enhance the vasoconstricting effect of Phenylephrine (Systemic).  Management: Do not use hyaluronidase to enhance the dispersion or absorption of phenylephrine. Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May diminish the therapeutic effect of Hyaluronidase.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49307275"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Hyaluronidase has been evaluated for use prior to intracytoplasmic sperm injection (ICSI) to aid the in vitro fertilization of human eggs (DeVos 2008; Evison 2009; Majumdar 2013; Moura 2017; Worrilow 2013).</p></div>
<div class="block pri drugH1Div" id="F179299"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse maternal or fetal events were not observed when used as an aid to delivery or an aid to conception. Administration during labor did not cause any increase in blood loss or differences in cervical trauma.</p></div>
<div class="block mopp drugH1Div" id="F53567149"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor injection site; monitor extravasation site.</p></div>
<div class="block pha drugH1Div" id="F179280"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Enzymatically modifies the permeability of connective tissue through hydrolysis of hyaluronic acid, one of the chief components of tissue cement which offers resistance to diffusion of liquids through tissues; hyaluronidase increases the distribution/dispersion and absorption of locally injected or extravasated IV medications.</p></div>
<div class="block phk drugH1Div" id="F179296"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: SubQ: Immediate; when used for extravasation, there is usually a reduction in swelling within 15 to 30 minutes after administration (Zenk 1981b)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 24 to 48 hours (variable)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038653"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Hylase dessau</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Hyalase</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Hyason</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Hylase</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Hyalozima</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Hyaiuronidase | Sod.hyaluronidase</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Hyasa | Hylase</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Hylase</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Hylase dessau | Lidaza m | Lydasum</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Hyason</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Hyalase</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Hyalase</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Hyalase</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Hyalase | Wockhardt hyalase | Wydase</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Hyase | Hyason</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Hyalase | Hyaluronidase</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Anvase | Entodase | Hinex | Hynidase</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Jaluran</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Spractor | Sprase</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Beauty ro | Bmhylunidase | Hidase | Hirax | Hirodase | Hrase | Hyalase | Hyalaze | Hyaline | Hyallap | Hyalnex | Hyalose | Hylase dessau | Hyloline | Hylunidase | Hyrondase | Ldl | Ldrase | Lipoderma | Liporase | Malinda | Medilase | Medirase | Mothers hyludase | Pcld | Purirax | Raneedase | Supofil | Union hyaluronidase</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Entodase | Hexalyse | Hylase | Lydasa | Ronidasa</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Hyasa | Hylase | Lydasa | Lydase | Lydazum | Ronidasa</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Hyalase</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Hyason</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Hylase dessau</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Hyalase</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Hyalase | Hylase</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Amphadase | Vitrase | Wydase</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Hyalase</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Hyalase</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Hyason</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Biogial | Longidaza | Lydasa | Lydase | Lyrase</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Hyalase</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Hyalas</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Wydase</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Hylase</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Hyasa</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Hyalase | Sprase</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Lydasa | Lydasa-biopharma</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19805455">
<a name="19805455"></a>Allen CH, Etzwiler LS, Miller MK, et al, "Recombinant Human Hyaluronidase-Enabled Subcutaneous Pediatric Rehydration," <i>Pediatrics</i>, 2009, 124(5):e858-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/19805455/pubmed" id="19805455" target="_blank">19805455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Allen.1">
<a name="Allen.1"></a>Allen CA, Etzwiler LS, Miller MK, et al, “Subcutaneous Hydration in Children Using Recombinant Human Hyaluronidase: Safety and Ease of Use,” <i>Ann Emerg Med</i>, 2008, 52(4 Suppl):75-6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACT.1">
<a name="ACT.1"></a>American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR manual on contrast media. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Published 2023. Accessed May 17, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amphadase.1">
<a name="Amphadase.1"></a>Amphadase (hyaluronidase) [prescribing information]. Rancho Cucamonga, CA: Amphastar Pharmaceuticals Inc; November 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barash.2009">
<a name="Barash.2009"></a>Barash PG, Cullen BF, Stoelting RK, et al, eds. <i>Clinical Anesthesia</i>. 6th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12386778">
<a name="12386778"></a>Bellin MF, Jakobsen JA, Tomassin I, et al; Contrast Media Safety Committee of the European Society of Urogenital Radiology. Contrast medium extravasation injury: guidelines for prevention and management. <i>Eur Radiol</i>. 2002;12(11):2807-2812.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/12386778/pubmed" id="12386778" target="_blank">12386778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21915003">
<a name="21915003"></a>Connolly S, Korzemba H, Harb G, et al, “Techniques for Hyaluronidase-Facilitated Subcutaneous Fluid Administration With Recombinant Human Hyaluronidase: The Increased Flow Utilizing Subcutaneously Enabled Administration Technique (INFUSE AT) Study,” <i>J Infus Nurs</i>, 2011, 34(5):300-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/21915003/pubmed" id="21915003" target="_blank">21915003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18540008">
<a name="18540008"></a>De Vos A, Van Landuyt L, Van Ranst H, et al, "Randomized Sibling-Oocyte Study Using Recombinant Human Hyaluronidase versus Bovine-Derived Sigma Hyaluronidase in ICSI Patients," <i>Hum Reprod</i>, 2008, 23(8):1815-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/18540008/pubmed" id="18540008" target="_blank">18540008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15151940">
<a name="15151940"></a>Ener RA, Meglathery SB, and Styler M, "Extravasation of Systemic Hemato-Oncological Therapies," <i>Ann Oncol</i>, 2004, 15(6):858-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/15151940/pubmed" id="15151940" target="_blank">15151940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19490785">
<a name="19490785"></a>Evison M, Pretty C, Taylor E, et al, "Human Recombinant Hyaluronidase (Cumulase) Improves Intracytoplasmic Sperm Injection Survival and Fertilization Rates," <i>Reprod Biomed Online,</i> 2009, 18(6):811-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/19490785/pubmed" id="19490785" target="_blank">19490785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8414723">
<a name="8414723"></a>Flemmer L and Chan JS, "A Pediatric Protocol for Management of Extravasation Injuries," <i>Pediatr Nurs</i>, 1993, 19(4):355-8, 424.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/8414723/pubmed" id="8414723" target="_blank">8414723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28947526">
<a name="28947526"></a>Fox AN, Villanueva R, Miller JL. Management of amiodarone extravasation with intradermal hyaluronidase. <i>Am J Health Syst Pharm</i>. 2017;74(19):1545-1548.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/28947526/pubmed" id="28947526" target="_blank">28947526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15192356">
<a name="15192356"></a>Hurst S and McMillan M, “Innovative Solutions in Critical Care Units: Extravasation Guidelines,” <i>Dimens Crit Care Nurs</i>, 2004, 23(3):125-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/15192356/pubmed" id="15192356" target="_blank">15192356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hylenex.1">
<a name="Hylenex.1"></a>Hylenex (hyaluronidase injection recombinant human) [prescribing information]. San Diego, CA: Halozyme Therapeutics Inc; January 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20417890">
<a name="20417890"></a>Kuensting LL. Treatment of intravenous infiltration in a neonate. <i>J Pediatr Health Care</i>. 2010;24:184-188.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/20417890/pubmed" id="20417890" target="_blank">20417890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11004052">
<a name="11004052"></a>Kallio H, Paloheimo M, and Maunuksela EL, “Hyaluronidase as an Adjuvant in Bupivacaine-Lidocaine Mixture for Retrobulbar/Peribulbar Block,” <i>Anesth Analg</i>, 2000, 91(4):934-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/11004052/pubmed" id="11004052" target="_blank">11004052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14500188">
<a name="14500188"></a>Kumar MM and Sprung J, “The Use of Hyaluronidase to Treat Mannitol Extravasation,” <i>Anesth Analg</i>, 2003, 97(4):1199-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/14500188/pubmed" id="14500188" target="_blank">14500188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12644428">
<a name="12644428"></a>Lai F, Sutton B, Nicholson G. Comparison of L-bupivacaine 0.75% and lidocaine 2% with bupivacaine 0.75% and lidocaine 2% for peribulbar anaesthesia. <i>Br J Anaesth</i>. 2003;90(4):512-514.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/12644428/pubmed" id="12644428" target="_blank">12644428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24714850">
<a name="24714850"></a>Le A, Patel S. Extravasation of noncytotoxic drugs: a review of the literature. <i>Ann Pharmacother</i>. 2014;48(7):870-886.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/24714850/pubmed" id="24714850" target="_blank">24714850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20482727">
<a name="20482727"></a>Lee A, Grummer SE, Kriegel D, et al. <i>Hyaluronidase</i>. Dermatol Surg. 2010;36(7):1071-1077.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/20482727/pubmed" id="20482727" target="_blank">20482727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6628223">
<a name="6628223"></a>MacCara ME. Extravasation - a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17:713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/6628223/pubmed" id="6628223" target="_blank">6628223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24085466">
<a name="24085466"></a>Majumdar G, Majumdar A. A prospective randomized study to evaluate the effect of hyaluronic acid sperm selection on the intracytoplasmic sperm injection outcome of patients with unexplained infertility having normal semen parameters.<i> J Assist Reprod Genet</i>. 2013;30(11):1471-1475. doi: 10.1007/s10815-013-0108-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/24085466/pubmed" id="24085466" target="_blank">24085466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12027856">
<a name="12027856"></a>Moharib MM, Mitra S, Rizvi SG. Effect of alkalinization and/or hyaluronidase adjuvancy on a local anesthetic mixture for sub-Tenon's ophthalmic block. <i>Acta Anaesthesiol Scand</i>. 2002;46(5):599-602.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/12027856/pubmed" id="12027856" target="_blank">12027856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28333029">
<a name="28333029"></a>Moura BR, Gurgel MC, Machado SP, et al. Low concentration of hyaluronidase for oocyte denudation can improve fertilization rates and embryo quality.<i> JBRA Assist Reprod.</i> 2017;21(1):27-30. doi: 10.5935/1518-0557.20170008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/28333029/pubmed" id="28333029" target="_blank">28333029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8610868">
<a name="8610868"></a>Nathan N, Benrhaiem M, Lotfi H, et al. The role of hyaluronidase on lidocaine and bupivacaine pharmacokinetics after peribulbar blockade. <i>Anesth Analg</i>. 1996;82(5):1060-1064.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/8610868/pubmed" id="8610868" target="_blank">8610868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22749221">
<a name="22749221"></a>Parmegiani L, Cognigni GE, Bernardi S, et al, "Comparison of Two Ready-To-Use Systems Designed for Sperm-Hyaluronic Acid Binding Selection Before Intracytoplasmic Sperm Injection: PICSI vs. Sperm Slow: A Prospective, Randomized Trial," <i>Fertil Steril</i>, 2012, 98(3):632-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/22749221/pubmed" id="22749221" target="_blank">22749221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al, “Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,” <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Polovich.2009">
<a name="Polovich.2009"></a>Polovich M, Whitford JN and Olsen M, <i>Chemotherapy and Biotherapy Guidelines and Recommendations for Practice</i>, 3rd ed, Pittsburgh, PA: Oncology Nursing Society, 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2358898">
<a name="2358898"></a>Raszka WV, Keuser TK, Smith FR, et al, “The Use of Hyaluronidase in the Treatment of Intravenous Extravasation Injuries,” <i>J Perinatol</i>, 1990, 10(2):146-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/2358898/pubmed" id="2358898" target="_blank">2358898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, Maclaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi: 10.1002/phar.1396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22633726">
<a name="22633726"></a>Rowlett J, “Extravasation of Contrast Media Managed With Recombinant Human Hyaluronidase,” <i>Am J Emerg Med</i>, 2012, 30(9):2102, e1-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/22633726/pubmed" id="22633726" target="_blank">22633726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21255716">
<a name="21255716"></a>Schulmeister L, "Extravasation Management: Clinical Update," <i>Semin Oncol Nurs</i>, 2011, 27(1):82-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/21255716/pubmed" id="21255716" target="_blank">21255716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sokol.1">
<a name="Sokol.1"></a>Sokol DK, Dahlmann A, Dunn DW. Hyaluronidase treatment for intravenous phenytoin extravasation. <i>Journal of child neurology</i>. 1998;13(5):246-247.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23062548">
<a name="23062548"></a>Spandorfer PR, Mace SE, Okada PJ, et al, "A Randomized Clinical Trial of Recombinant Human Hyaluronidase-Facilitated Subcutaneous versus Intravenous Rehydration in Mild to Moderately Dehydrated Children in the Emergency Department," <i>Clin Ther</i>, 2012, 34(11):2232-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/23062548/pubmed" id="23062548" target="_blank">23062548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12690542">
<a name="12690542"></a>Stanford BL, Hardwicke F. A review of clinical experience with paclitaxel extravasations. <i>Support Care Cancer</i>. 2003;11(5):270-277. doi: 10.1007/s00520-003-0441-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/12690542/pubmed" id="12690542" target="_blank">12690542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11576046">
<a name="11576046"></a>van den Berg AA, Montoya-Pelaez LF. Comparison of lignocaine 2% with adrenaline, bupivacaine 0.5% with or without hyaluronidase and a mixture of bupivacaine, lignocaine and hyaluronidase for peribulbar block analgesia. <i>Acta Anaesthesiol Scand</i>. 2001;45(8):961-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/11576046/pubmed" id="11576046" target="_blank">11576046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vitrase.1">
<a name="Vitrase.1"></a>Vitrase (hyaluronidase ovine) injection [prescribing information]. Bridgewater, NJ: Bausch &amp; Lomb Americas Inc; January 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27468136">
<a name="27468136"></a>Wasserman RL, Melamed I, Kobrynski L, et al. Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability. <i>Immunotherapy</i>. 2016a;8(10):1175‐1186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/27468136/pubmed" id="27468136" target="_blank">27468136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27220317">
<a name="27220317"></a>Wasserman RL, Melamed I, Stein MR, et al. Long-term tolerability, safety, and efficacy of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulin for primary immunodeficiency. <i>J Clin Immunol</i>. 2016b;36(6):571‐582.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/27220317/pubmed" id="27220317" target="_blank">27220317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22846381">
<a name="22846381"></a>Wasserman RL, Melamed I, Stein MR, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. <i>J Allergy Clin Immunol</i>. 2012;130(4):951‐7.e11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/22846381/pubmed" id="22846381" target="_blank">22846381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20159411">
<a name="20159411"></a>Weigand R and Brown J, “Hyaluronidase for the Management of Dextrose Extravasation,” <i>Am J Emerg Med</i>, 2010, 28(2):257.e1-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/20159411/pubmed" id="20159411" target="_blank">20159411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23203216">
<a name="23203216"></a>Worrilow KC, Eid S, Woodhouse D, et al. Use of hyaluronan in the selection of sperm for intracytoplasmic sperm injection (ICSI): significant improvement in clinical outcomes--multicenter, double-blinded and randomized controlled trial. <i>Hum Reprod.</i> 2013;28(2):306-314. doi: 10.1093/humrep/des417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/23203216/pubmed" id="23203216" target="_blank">23203216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zenk.1981.a">
<a name="Zenk.1981.a"></a>Zenk KE, “Hyaluronidase: An Antidote for Intravenous Extravasations,” <i>CSHP Voice</i>, 1981a, 66-8.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zenk.1981.b">
<a name="Zenk.1981.b"></a>Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981b;5:77-79.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7315807">
<a name="7315807"></a>Zenk KE, Dungy CI, and Greene GR, “Nafcillin Extravasation Injury: Use of Hyaluronidase as an Antidote,” <i>Am J Dis Child</i>, 1981c, 135(12):1113-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/7315807/pubmed" id="7315807" target="_blank">7315807</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13355 Version 184.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
